CureVac N.V (NASDAQ: CVAC) open the trading on Wednesday, with great promise as it jumped 4.74% to $2.87, before settling in for the price of $2.74 at the close. Taking a more long-term approach, CVAC posted a 52-week range of $2.21-$6.30.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 54.58%. Meanwhile, its Annual Earning per share during the time was -23.15%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 167.40%. This publicly-traded company’s shares outstanding now amounts to $223.99 million, simultaneously with a float of $93.63 million. The organization now has a market capitalization sitting at $674.30 million. At the time of writing, stock’s 50-day Moving Average stood at $2.84, while the 200-day Moving Average is $3.18.
CureVac N.V (CVAC) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. CureVac N.V’s current insider ownership accounts for 58.26%, in contrast to 5.18% institutional ownership.
CureVac N.V (CVAC) Earnings and Revenue Records
CureVac N.V’s EPS increase for this current 12-month fiscal period is 167.40% and is forecasted to reach -0.54 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -10.76% through the next 5 years, which can be compared against the -23.15% growth it accomplished over the previous five years trading on the market.
CureVac N.V (NASDAQ: CVAC) Trading Performance Indicators
Let’s observe the current performance indicators for CureVac N.V (CVAC). It’s Quick Ratio in the last reported quarter now stands at 6.19. The Stock has managed to achieve an average true range (ATR) of 0.16. Alongside those numbers, its PE Ratio stands at $5.28, and its Beta score is 2.58. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.13. Similarly, its price to free cash flow for trailing twelve months is now 5.96.
In the same vein, CVAC’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.54, a figure that is expected to reach -0.22 in the next quarter, and analysts are predicting that it will be -0.54 at the market close of one year from today.
Technical Analysis of CureVac N.V (CVAC)
[CureVac N.V, CVAC] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 82.63% While, its Average True Range was 0.17.
Raw Stochastic average of CureVac N.V (CVAC) in the period of the previous 100 days is set at 33.33%, which indicates a major fall in contrast to 83.33% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 50.58% that was lower than 53.20% volatility it exhibited in the past 100-days period.
